Oenon Holdings (2533) FY2026 Q1 Earnings Report

Quick View

Executive Summary

In Q1 of FY2026, Oenon Holdings posted a substantial increase in profit, driven by higher revenue from alcoholic beverages and strong growth in enzyme pharmaceuticals. The key highlight was that gross profit improvement boosted operating income. Revenue was ¥21.27B (+9.5% YoY), operating income was ¥1.27B (+81.9%), ordinary income was ¥1.31B (+83.5%), and net income attributable to owners of the parent was ¥0.94B (+75.2%). The gross profit margin improved to 18.8% from 16.7% in the same period of the previous year, while the SG&A expense growth rate (+7.3%) remained below the revenue growth rate, resulting in operating leverage. The primary driver of profit growth was improved profitability in the core business, while the impact of non-operating and extraordinary gains and losses was limited.

Factors Affecting Business Performance

【Revenue】Revenue increased 9.5% YoY to ¥21.27B. The core alcoholic beverages business led growth, generating ¥19.41B (+8.5% YoY) and accounting for 91.3% of total revenue, while enzyme pharmaceuticals continued to deliver strong growth, generating ¥1.50B (+26.8% YoY). Real estate revenue was ¥0.33B (+0.6% YoY), remaining broadly flat.

【Profit and Loss】Operating income increased substantially to ¥1.27B (+81.9% YoY), ordinary income to ¥1.31B (+83.5%), and net income to ¥0.94B (+75.2%). Segment profit in alcoholic beverages was ¥0.63B (+167.9% YoY), substantially exceeding the rate of revenue growth, and the segment margin improved from 1.3% to 3.3%. Segment profit in enzyme pharmaceuticals was ¥0.43B (+65.4% YoY), maintaining a high margin of 28.6% and contributing to the improvement in the Company-wide profit margin. Non-operating income and expenses resulted in only ¥0.045B of net income, while extraordinary losses were minimal at ¥0.001B. Accordingly, profit growth was attributable to improved profitability in the core business. In conclusion, the Company achieved both revenue and profit growth, with improved profitability in alcoholic beverages being the primary driver of Company-wide profit growth.

Segment Analysis

The alcoholic beverages segment generated revenue of ¥19.41B (+8.5% YoY) and segment profit of ¥0.63B (+167.9%), with its margin improving from 1.3% to 3.3%. Although it is the core business, accounting for 91.3% of the revenue mix, its margin remains low compared with other segments. Enzyme pharmaceuticals generated revenue of ¥1.50B (+26.8%), segment profit of ¥0.43B (+65.4%), and a margin of 28.6%, achieving both strong growth and high profitability and contributing significantly to Company-wide profit improvement. Real estate generated revenue of ¥0.33B (+0.6%), segment profit of ¥0.20B (+1.5%), and a margin of 59.6%; although small in scale, it remains a stable source of high profitability. Contributions to Company-wide operating income were 50.1% from alcoholic beverages, 34.0% from enzyme pharmaceuticals, and 15.6% from real estate. The expanding contribution from enzyme pharmaceuticals indicates a qualitative improvement in the earnings mix.

Key Financial Indicators

【Profitability】The operating margin improved to 6.0% from 3.6% in the same period of the previous year, while the net profit margin also improved to 4.4% from 2.8%. The increase in gross profit margin to 18.8% from 16.7% and the decline in the SG&A expense ratio to 12.8% from 13.1% supported the profit increase.【Cash Flow Quality】Cash and deposits were ¥0.73B, while non-operating income was small, at less than ¥0.05B. The profit increase was therefore of high quality, resulting from operational improvements in the core business.【Investment Efficiency】Annualized ROE was 13.7%, with net profit margin, total asset turnover, and financial leverage each contributing in a balanced manner.【Financial Soundness】The equity ratio improved to 50.2% from approximately 44.2% in the previous year. However, short-term borrowings doubled to ¥4.05B from ¥1.95B, indicating a shift toward shorter-term interest-bearing debt. Short-term borrowings of ¥4.05B are large relative to cash and deposits of ¥0.73B, necessitating liquidity monitoring.

Cash Flow Analysis

As the cash flow statement has not been disclosed, cash flow trends are analyzed based on balance sheet movements. Cash and deposits were ¥0.73B, slightly down from ¥0.88B in the same period of the previous year. Short-term borrowings increased 107.7% to ¥4.05B from ¥1.95B in the same period of the previous year, while long-term borrowings declined 50.0% to ¥0.30B from ¥0.60B, indicating a shift toward shorter-term financing. Accounts receivable of ¥15.22B and inventories of ¥7.53B represent substantial asset balances, creating a structure in which collection and management of these assets affect capital efficiency. Net assets increased to ¥27.43B from ¥26.98B in the previous year, with accumulated retained earnings and profit growth supporting the capital base.

Earnings Quality

The profit increase in the current quarter was of high quality, led by improvements in the core business rather than dependent on non-operating or extraordinary gains and losses. Non-operating income was ¥0.10B, including ¥0.02B in dividend income, while non-operating expenses were ¥0.06B, including ¥0.04B in interest expense, resulting in net income of only ¥0.045B. Its contribution to ordinary income of ¥1.31B was therefore limited. Extraordinary losses were minimal at ¥0.001B, and the difference between profit before tax of ¥1.31B and operating income of ¥1.27B can be explained almost entirely by non-operating gains and losses. Structural factors—namely, the improvement in gross profit margin from 16.7% to 18.8% and the decline in the SG&A expense ratio from 13.1% to 12.8%—were central to the profit increase, with no evidence of a boost from temporary factors. Comprehensive income was ¥1.08B, and the difference from net income of ¥0.94B was primarily attributable to ¥0.17B in valuation difference on securities, broadly consistent with the earnings power of the underlying business.

Earnings Forecast and Guidance

Q1 progress against the full-year forecast was 23.9% for revenue, 32.1% for operating income, 32.8% for ordinary income, and 32.4% for net income. All were above the standard quarterly progress benchmark of 25%, representing a strong start. However, the Company’s full-year forecast assumes YoY declines of 4.5% in operating income and 6.8% in ordinary income. Whether the high Q1 operating margin of 6.0% can be maintained throughout the year will therefore be a key focus. The Company has not revised either its earnings forecast or dividend forecast. The full-year forecast operating margin of 4.4% is below the Q1 result, suggesting that increases in raw material, logistics, and other costs may be incorporated into the outlook for the second half.

Shareholder Returns

The full-year dividend forecast is ¥12.00 per share, an increase from ¥11 in the previous year. The payout ratio against forecast full-year EPS of ¥51.47 is approximately 23.3%. This payout ratio is significantly below the general sustainability benchmark of 60% and remains conservative relative to the earnings level. There was no revision to the dividend forecast during the current quarter. As the implementation status of share repurchases cannot be confirmed from the disclosed data, the payout ratio is evaluated based solely on dividends.

Risk Factors

1. Business concentration risk: Alcoholic beverages account for 91.3% of revenue, creating a structure in which demand for alcoholic beverages, the competitive environment, acceptance of price revisions, and changes in consumer preferences could materially affect consolidated performance.

2. Dependence on short-term financing: Short-term borrowings of ¥4.05B account for the majority of interest-bearing debt and increased 107.7% from ¥1.95B in the same period of the previous year. Cash and deposits remain limited at ¥0.73B, resulting in a low cash-to-short-term liabilities ratio.

3. Gross profit margin level: Although the gross profit margin of 18.8% is improving, it remains below the 25% level generally considered healthy in the food and beverage industry. The ability to pass increases in raw material, energy, and logistics costs on to customers will affect future margins.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (food_beverage)

Profitability and Returns

As comparative data against the industry median has not been provided for the Company’s profitability indicators, discussion is limited to the absolute levels.

Growth and Capital Efficiency

Industry median data is also unavailable for revenue growth; therefore, only the Company’s performance is presented.

※Source: Compiled by the Company

Key Points in the Earnings Results

1. Operating income increased 81.9% against revenue growth of +9.5%, clearly demonstrating operating leverage resulting from the improvement in gross profit margin from 16.7% to 18.8% and the decline in the SG&A expense ratio from 13.1% to 12.8%.

2. While the alcoholic beverages segment’s margin improved at a pace exceeding revenue growth, from 1.3% to 3.3%, enzyme pharmaceuticals, with a margin of 28.6%, and real estate, with a margin of 59.6%, continued to supplement Company-wide margins as highly profitable segments.

3. Full-year progress was favorable, at approximately 32% on a profit basis. However, the Company’s full-year forecast itself assumes a YoY decline in profit, making whether the high Q1 margin can be maintained throughout the year dependent on future cost trends a key structural point of focus.

Theoretical Stock Price (Reference Value)

Sensitivity: ¥492–¥521 at ±1% for the cost of equity, and ¥506–¥507 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used; there is a timing difference from the full-year forecast.
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest Rate Reference Month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---